MX368484B - Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. - Google Patents
Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.Info
- Publication number
- MX368484B MX368484B MX2014007183A MX2014007183A MX368484B MX 368484 B MX368484 B MX 368484B MX 2014007183 A MX2014007183 A MX 2014007183A MX 2014007183 A MX2014007183 A MX 2014007183A MX 368484 B MX368484 B MX 368484B
- Authority
- MX
- Mexico
- Prior art keywords
- immune response
- response against
- humoral immune
- vaccination
- producing
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 230000028996 humoral immune response Effects 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 241001138401 Kluyveromyces lactis Species 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011121069A DE102011121069A1 (de) | 2011-12-13 | 2011-12-13 | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
| PCT/DE2012/001205 WO2013107436A1 (de) | 2011-12-13 | 2012-12-12 | Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007183A MX2014007183A (es) | 2014-11-25 |
| MX368484B true MX368484B (es) | 2019-10-04 |
Family
ID=47681476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007183A MX368484B (es) | 2011-12-13 | 2012-12-12 | Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11065312B2 (enExample) |
| EP (1) | EP2844759B1 (enExample) |
| JP (1) | JP6313215B2 (enExample) |
| KR (1) | KR102027400B1 (enExample) |
| CN (1) | CN104428417B (enExample) |
| BR (1) | BR112014014390B1 (enExample) |
| CA (1) | CA2859231C (enExample) |
| DE (2) | DE102011121069A1 (enExample) |
| DK (1) | DK2844759T3 (enExample) |
| ES (1) | ES2690792T3 (enExample) |
| MX (1) | MX368484B (enExample) |
| PL (1) | PL2844759T3 (enExample) |
| RU (1) | RU2630620C2 (enExample) |
| WO (1) | WO2013107436A1 (enExample) |
| ZA (1) | ZA201405034B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102017012109A1 (de) * | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| CN109467606A (zh) * | 2018-11-15 | 2019-03-15 | 大连理工大学 | 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用 |
| JP7372647B2 (ja) * | 2019-06-27 | 2023-11-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | α‐リノレン酸産生能が向上した酵母またはその培養物 |
| CN110646614B (zh) * | 2019-07-15 | 2023-05-23 | 新乡学院 | Ibdv抗体的elisa试剂盒和测试方法、有效抗体效价确定方法 |
| CN114870006B (zh) * | 2022-04-13 | 2026-06-02 | 河北农业大学 | 一种etec疫苗及其应用 |
| WO2026119376A1 (de) | 2024-12-03 | 2026-06-11 | Verovaccines Gmbh | Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643216B2 (en) * | 1989-05-30 | 1993-11-11 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US6234977B1 (en) | 2000-01-28 | 2001-05-22 | Michael Christy | Variable-force monofilament sensory device and methods of using same |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| KR101085310B1 (ko) * | 2003-03-24 | 2011-11-22 | 인터벳 인터내셔널 비.브이. | 감염성 점액낭병 바이러스 돌연변이체 및 백신 |
| ES2242542B1 (es) * | 2004-04-30 | 2006-12-16 | Consejo Superior De Investigaciones Cientificas | Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv). |
| WO2006078318A2 (en) * | 2004-07-29 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| KR20070068460A (ko) | 2004-10-18 | 2007-06-29 | 글로브이뮨 | 만성 ｃ형 간염에 대한 효모계 치료 |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| WO2008153339A2 (en) * | 2007-06-12 | 2008-12-18 | Univ Sungkyunkwan Found | A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system |
| DE102008057451A1 (de) * | 2008-11-14 | 2010-05-20 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen |
| CN101638824B (zh) | 2009-03-16 | 2012-08-08 | 浙江双友物流器械股份有限公司 | 一种耐磨织带 |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
-
2011
- 2011-12-13 DE DE102011121069A patent/DE102011121069A1/de not_active Ceased
-
2012
- 2012-12-12 MX MX2014007183A patent/MX368484B/es active IP Right Grant
- 2012-12-12 PL PL12823073T patent/PL2844759T3/pl unknown
- 2012-12-12 WO PCT/DE2012/001205 patent/WO2013107436A1/de not_active Ceased
- 2012-12-12 KR KR1020147019123A patent/KR102027400B1/ko active Active
- 2012-12-12 CN CN201280062015.XA patent/CN104428417B/zh active Active
- 2012-12-12 RU RU2014127435A patent/RU2630620C2/ru active
- 2012-12-12 CA CA2859231A patent/CA2859231C/en active Active
- 2012-12-12 JP JP2014546315A patent/JP6313215B2/ja active Active
- 2012-12-12 ES ES12823073.7T patent/ES2690792T3/es active Active
- 2012-12-12 BR BR112014014390-0A patent/BR112014014390B1/pt active IP Right Grant
- 2012-12-12 EP EP12823073.7A patent/EP2844759B1/de active Active
- 2012-12-12 DK DK12823073.7T patent/DK2844759T3/en active
- 2012-12-12 DE DE112012005213.7T patent/DE112012005213A5/de not_active Withdrawn
- 2012-12-12 US US14/364,238 patent/US11065312B2/en active Active
-
2014
- 2014-07-10 ZA ZA2014/05034A patent/ZA201405034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104428417A (zh) | 2015-03-18 |
| JP2015507472A (ja) | 2015-03-12 |
| PL2844759T3 (pl) | 2019-01-31 |
| MX2014007183A (es) | 2014-11-25 |
| EP2844759B1 (de) | 2018-07-18 |
| DE112012005213A5 (de) | 2014-11-13 |
| US11065312B2 (en) | 2021-07-20 |
| DK2844759T3 (en) | 2018-11-05 |
| RU2630620C2 (ru) | 2017-09-11 |
| CN104428417B (zh) | 2020-05-05 |
| ZA201405034B (en) | 2015-12-23 |
| WO2013107436A8 (de) | 2015-01-15 |
| BR112014014390A2 (pt) | 2020-12-08 |
| KR102027400B1 (ko) | 2019-10-04 |
| ES2690792T3 (es) | 2018-11-22 |
| KR20140105821A (ko) | 2014-09-02 |
| EP2844759A1 (de) | 2015-03-11 |
| RU2014127435A (ru) | 2016-02-10 |
| DE102011121069A1 (de) | 2013-06-13 |
| CA2859231A1 (en) | 2013-07-25 |
| US20150190486A1 (en) | 2015-07-09 |
| WO2013107436A1 (de) | 2013-07-25 |
| CA2859231C (en) | 2019-04-30 |
| JP6313215B2 (ja) | 2018-04-18 |
| BR112014014390B1 (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201301013B (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| PH12017500727A1 (en) | Modified virus-like particles of cmv | |
| IN2014CN02136A (enExample) | ||
| MY181688A (en) | Improved production of fatty acid derivatives | |
| WO2013054199A3 (en) | Cmv antigens and uses thereof | |
| WO2013107436A8 (de) | Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene | |
| WO2012149307A3 (en) | Synthetic long peptide (slp)-based vaccines | |
| NZ705606A (en) | Methods for identifying antibodies with reduced immunogenicity | |
| MX2013007918A (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| MX350096B (es) | Preservación asistida con vacío de productos biológicos, en particular de vacunas. | |
| WO2012142302A3 (en) | Biocatalytic process for preparing eslicarbazepine and analogs thereof | |
| NZ715459A (en) | A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same | |
| HK1202070A1 (zh) | 用於肿瘤免疫疗法的疫苗 | |
| SG10201808644PA (en) | Recombinant mycobacterium as a vaccine | |
| WO2012112416A3 (en) | Method of producing n-butyraldehyde | |
| IN2015DN03026A (enExample) | ||
| WO2013019603A3 (en) | Linear expression cassettes and uses thereof | |
| IN2014CN02963A (enExample) | ||
| NZ603431A (en) | Parapoxvirus vectors containing rabies virus antigen | |
| WO2011100508A3 (en) | Methods and compositions related to glycoprotein-immunoglobulin fusions | |
| EA028913B9 (ru) | Получение антител высокой чистоты в pichia pastoris | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| MX374919B (es) | ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae. | |
| GB201120634D0 (en) | Adjuvant polypeptide | |
| MX337687B (es) | Linea celular de amniocitos humanos permanente para la produccion de virus de influenza. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |